ESMO 2024: Treatment Breakthroughs in Pretreated Patients with Advanced or Metastatic NSCLC With or Without Actionable Genomic Alterations - Episode 10
Adverse Event Management and Resistance Mechanisms: Key Considerations for Datopotamab Deruxtecan in Advanced NSCLC
This episode addresses strategies for mitigating and managing adverse events associated with Dato-DXd in patients with advanced NSCLC, explores how the drug’s structure may help prevent acquired resistance mechanisms that are common with TKIs, and discusses the broader implications of integrating Dato-DXd and other ADCs into the treatment landscape for this patient population.
Video content above is prompted by the following:
- How would you mitigate or manage grade >3 Dato-DXd–related adverse events among your patients with advanced or metastatic NSCLC?
- How might the structure and function of Dato-DX-d deter the development of acquired resistance mechanisms observed with TKIs in this AGA population?
- How does the armamentarium expand here?
Related Content:
